Fig. 1From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registryJuvenile Disease Activity Score 10 (JADAS-10) remission (defined as JADAS ≤1) and JADAS minimal disease activity (defined as JADAS ≤3.8). The number of patient contributing to the calculation is given below the figure. TOC, tocilizumab; ETA, etanercept; IL-1i, interleukin-1 inhibitor; ACR, American College of RheumatologyBack to article page